CT Image Based Closest-to-tumor Radiation in Cervical Cancer
- Conditions
- Health Condition 1: C538- Malignant neoplasm of overlappingsites of cervix uteri
- Registration Number
- CTRI/2022/11/047633
- Lead Sponsor
- Chittaranjan National Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients of cervical cancer sent from multidisciplinary tumor board after being proved on histopathology (squamous cell or adenocarcinoma) with FIGO stage IB2 to III
2.Eastern Cooperative Oncology Group performance status upto 2
3.Hemoglobin >10 gm%, Total leukocyte count > 4000 cells/cmm, Platelet count > 1,00,000 cells/cmm (initially or after correction by blood transfusion).
4.Liver function test- AST < 2×Upper normal limit, bilirubin <2×upper normal limit
Kidney function test- Serum creatinine <1.5 mg/dL and calculated creatinine clearance using the Cockroft-Gault formula >50 ml/min
5.Patient with no history or current clinical evidence of any hematological or bleeding disorders
6.No history of drug use which results in hematological toxicity
7.HBsAg, Anti-HCV, HIV-I & -II Antibody non-reactive patients.
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the feasibility of delineating HR-CTV on CT image following IBS-GEC ESTRO-ABS recommendations & Pre- & Post-EBRT MRI images. <br/ ><br>Computation of target coverage along with the doses received at Point A. <br/ ><br>To compare the doses received by bladder, rectum & bowel as per volume-based dose prescription and Point A-based dose prescription. <br/ ><br>Timepoint: At baseline
- Secondary Outcome Measures
Name Time Method To assess the treatment response & toxicity with special attention to Gastrointestinal (GI) & Genitourinary(GU) toxicity. <br/ ><br>Timepoint: At baseline,4 weeks,8weeks,12 weeks,6months,yearly